High call volumes
Our member and provider services may be experiencing higher than normal call volumes from 12/22/25-1/9/26 due to a large number of staff being out of office. We encourage you to utilize alternative forms of communication including secured messaging through online Member Services and Availity Essentials Provider Portal.
We are unable to accept walk-ins on Friday, Jan. 2., due to short staffing.
Beginning Jan. 1, 2026, Lisdexamfetamine (generic Vyvanse) will be preferred on the BCBSND Formulary and Health Insurance Marketplace (HIM) formulary. Brand name Vyvanse will be a non-formulary/non-preferred medication on these formularies starting Jan. 1, 2026.
Current Vyvanse utilizers on the Blue Cross Blue Shield of North Dakota (BCBSND) or HIM formularies will be allowed to continue filling Vyvanse at the formulary rate until March 31, 2026. As this is a brand-to-generic change, new prescriptions should not be needed at the pharmacy.
This formulary update does not impact the NetResults formulary as Lisdexamfetamine is already the formulary agent and Vyvanse is non-formulary.
